Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients

Platelets

Volumn 9, Issue 5, 1998, Pages 309-314

  Pignatelli, P ^a   Properzi, E ^a   Pisani, M ^a   Clerico, A ^a   Schiavetti, A ^a   Lenti, L ^a   Pulcinelli, F M ^a   Ferroni, P ^a   Gazzaniga, P P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CARBOPLATIN; COLLAGEN; ETOPOSIDE; PADGEM PROTEIN;

ADOLESCENT; ARTICLE; BRAIN TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; TIME;

EID: 0031665040     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109876555     Document Type: Article

References (26)

1. White JG. Effects of colchicine and Vinca alkaloids on human platelets. Am J Pathol 1969; 54: 467-73.
2. Steinherz PG, Miller DR, Hilgartner MW, Schalzer EA. Platelet function in vincristine treated patients. Br J Haematol 1976; 32: 439-50.
3. Ahr DJ, Scialla SJ, Kimball DB. Acquired platelet dysfunction following mithramicin therapy. Cancer 1978; 41: 448-54.
4. Kumar A, Khanna NN, Khanna S, Gupta YN. Qualitative platelet dysfunction following cancer CHT: a case. J Surg Oncol 1984; 25: 176-7.
5. Panella TJ, Peters W, White JG, Hannun YA, Greenberg CS. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 1990; 65: 1711-6.
6. Matera C, Falzarano C, Vacca C, Falciani M, Rossi F. Effects of some antineoplastic drugs (vincristine, doxorubicin and epirubicin) on human platelet aggregation. J Med 1994; 25: 2-16.
7. Monto RW, Talley RW, Caldwell MJ, Levin WC, Guest MM. Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24559) therapy. Cancer Res 1969; 29: 697-704.
8. Karolac L, Chandra A, Khan W, Marks B, Petros WP, Greenberg CS, Hannun YA. High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol 1993; 43: 37-44.
9. Shapiro RS, Gerrard JM, Ramsay NK, Nesbit ME, Coccia PF, Stoddard SF, Plow EF, White JG, Krivit W. Selective deficiency in collagen-induced platelet aggregation during L-asparaginase therapy. Am J Peadiatr Hematol Oncol 1980; 2: 207-12.
10. Pui CH, Jackson CW, Cesney C, Lyles SA, Bowman WP, Abromowitch M, Simone JV. Sequential changes in platelet function by prednisone, and vincristine. J Clin Oncol 1983; 1: 380-5.
11. Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A. High-dose carboplatin in combination with etoposide (JET Regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 1990; 3: 297-300.
12. Castello MA, Schiavetti A, Padula A, Varrasso G, Properzi E, Operamolla P, Gualdi GF, Clerico A. Does chemotherapy have a role in low-grade astrocytoma management? Report of 13 cases. Med ped Oncol 1995; 25: 102-8.
13. Born GVR. The aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-35.
14. Costa JJ, Murphy DL. Platelet 5-HT uptake and release stopped rapidly by formaldehyde. Nature 1975; 255: 405-16.
15. Holmsen H, Setkowsky-Dangelmaier CA. Adenosine nucleotide metabolism of blood platelets. X. Formaldehyde stops centrifugation-induced secretion after A23187 stimulation and causes breakdown of metabolic ATP. Biochim Biophys Acta 1997; 46: 497-500.
16. van Maanen JMS, Retèl J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80: 1526-33.
17. Teicher BA, Holden SA, Rose CM. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J Natl Cancer Inst 1985; 75: 1129-33.
18. Teicher BA, Bernal SD, Holden SA, Cathcart KN. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity. Cancer Chemother Pharmacol 1988; 21: 281-5.
19. Katki AG, Kalyanaraman B, Sinha BK. Interaction of the antitumor drug, etoposide, with reduced thiols in vitro and in vivo. Chem Biol Interact 1987; 62: 237-47.
20. Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Comm 1994; 203: 1175-80.
21. Canoso RT, Rodvien R, Scoon K, Levine PH. Hydrogen peroxide and platelet function. blood 1974; 43: 645-56.
22. Holmsen H, Robkin L. Hydrogen peroxide lowers ATP levels in platelets without altering adenylate energy charge and platelet function. J Biol Chem 1977; 252: 1752-7.
23. Levine PH, Weinger RS, Simon J, Scoon KL, Krinsky NI. Leukocyte-platelet interaction. Release of hydrogen peroxide by granulocytes as a modulator of platelet reactions. J Clin Invest 1976; 57: 955-63.
24. Rodvien R, Lindon JN, Levine PH. Physiology and ultrastructure of the blood platelet following exposure to hydrogen peroxide. Br J Haematol 1976; 33: 19-26.
25. Stuart MJ, Holmsen H. Hydrogen peroxide, an inhibitor of platelet function: effect on adenine nucleotide metabolism, and the release reaction. Am J Hematol 1977; 2: 53-63.
26. Ambrosio G, Golino P, Pascucci I, Rosolowsky M, Campbell WB, DeClerck F, Tritto I, Chiariello M. Modulation of platelet function by reactive oxygen metabolites. Am J Physiol 1994; 267: H308-18.